[go: up one dir, main page]

WO2024073106A8 - Compounds and compositions useful as inhibitors of iaps - Google Patents

Compounds and compositions useful as inhibitors of iaps Download PDF

Info

Publication number
WO2024073106A8
WO2024073106A8 PCT/US2023/034219 US2023034219W WO2024073106A8 WO 2024073106 A8 WO2024073106 A8 WO 2024073106A8 US 2023034219 W US2023034219 W US 2023034219W WO 2024073106 A8 WO2024073106 A8 WO 2024073106A8
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
iaps
inhibitors
compositions useful
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/034219
Other languages
French (fr)
Other versions
WO2024073106A1 (en
Inventor
Richard E. RUSSELL
William W. Bachovchin
Hung-Sen Lai
Wengen Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tract Pharmaceuticals Inc
Tufts University
Original Assignee
Tract Pharmaceuticals Inc
Tufts University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tract Pharmaceuticals Inc, Tufts University filed Critical Tract Pharmaceuticals Inc
Priority to JP2025518779A priority Critical patent/JP2025535017A/en
Priority to EP23873679.7A priority patent/EP4593818A1/en
Priority to CN202380070237.4A priority patent/CN120302969A/en
Priority to IL319844A priority patent/IL319844A/en
Priority to KR1020257013853A priority patent/KR20250093324A/en
Priority to AU2023350829A priority patent/AU2023350829A1/en
Publication of WO2024073106A1 publication Critical patent/WO2024073106A1/en
Publication of WO2024073106A8 publication Critical patent/WO2024073106A8/en
Priority to MX2025003568A priority patent/MX2025003568A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
PCT/US2023/034219 2022-09-29 2023-09-29 Compounds and compositions useful as inhibitors of taps Ceased WO2024073106A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2025518779A JP2025535017A (en) 2022-09-29 2023-09-29 Compounds and compositions useful as inhibitors of IAPs
EP23873679.7A EP4593818A1 (en) 2022-09-29 2023-09-29 Compounds and compositions useful as inhibitors of iaps
CN202380070237.4A CN120302969A (en) 2022-09-29 2023-09-29 Compounds and compositions useful as IAP inhibitors
IL319844A IL319844A (en) 2022-09-29 2023-09-29 Compounds and compositions useful as inhibitors of iaps
KR1020257013853A KR20250093324A (en) 2022-09-29 2023-09-29 Compounds and compositions useful as IAP inhibitors
AU2023350829A AU2023350829A1 (en) 2022-09-29 2023-09-29 Compounds and compositions useful as inhibitors of iaps
MX2025003568A MX2025003568A (en) 2022-09-29 2025-03-26 Compounds and compositions useful as inhibitors of iaps

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263411550P 2022-09-29 2022-09-29
US63/411,550 2022-09-29

Publications (2)

Publication Number Publication Date
WO2024073106A1 WO2024073106A1 (en) 2024-04-04
WO2024073106A8 true WO2024073106A8 (en) 2024-11-07

Family

ID=90479010

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/034219 Ceased WO2024073106A1 (en) 2022-09-29 2023-09-29 Compounds and compositions useful as inhibitors of taps

Country Status (8)

Country Link
EP (1) EP4593818A1 (en)
JP (1) JP2025535017A (en)
KR (1) KR20250093324A (en)
CN (1) CN120302969A (en)
AU (1) AU2023350829A1 (en)
IL (1) IL319844A (en)
MX (1) MX2025003568A (en)
WO (1) WO2024073106A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025090605A1 (en) * 2023-10-24 2025-05-01 University Of Houston System Combination of iap inhibitors and cellular kinase inhibitors, such as ponatinib, for use in the treatment of cancer or pulmonary diseases, such as copd, cystic fibrosis, pulmonary fibrosis and covid-19
WO2025217052A1 (en) * 2024-04-08 2025-10-16 University Of Houston System Combinations of an iap inhibtor, a tyrosine kinase inhibitor and an activator of the tnf a induced cell death pathway and their use in the treatment of proliferative diseases or disorders such as cancer or pulmonary diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008245447C1 (en) * 2007-04-30 2014-11-20 Genentech, Inc. Inhibitors of IAP
CN108289964B (en) * 2015-08-10 2022-08-12 杭州多禧生物科技有限公司 Novel linkers and their specific conjugation for drugs and biomolecules

Also Published As

Publication number Publication date
CN120302969A (en) 2025-07-11
IL319844A (en) 2025-05-01
MX2025003568A (en) 2025-07-01
KR20250093324A (en) 2025-06-24
EP4593818A1 (en) 2025-08-06
WO2024073106A1 (en) 2024-04-04
JP2025535017A (en) 2025-10-22
AU2023350829A1 (en) 2025-04-03

Similar Documents

Publication Publication Date Title
WO2023147594A3 (en) Irak degraders and uses thereof
WO2024073106A8 (en) Compounds and compositions useful as inhibitors of iaps
WO2005115398A3 (en) Hiv integrase inhibitors
ZA202207667B (en) Sulfonimidamide compounds as nlrp3 modulators
EP4491635A3 (en) Anti-ccr8 antibodies
MX2021003232A (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors.
WO2022104153A3 (en) Compounds and methods for treating viral infections
WO2022032073A3 (en) Trpml modulators
CR20220255A (en) Egfr inhibitors
WO2023122260A3 (en) Inhibitors of sars-cov-2
WO2022272036A9 (en) Tead inhibitors and uses thereof
WO2022031862A3 (en) Heteroaryl and heterocyclyl compounds
WO2018096525A3 (en) Heteroaryl compounds and uses thereof
WO2024220937A3 (en) Tyk2 degraders and uses thereof
WO2022074459A3 (en) Autotaxin inhibitor compounds
EP4480956A3 (en) Viral inhibitors, the synthesis thereof, and intermediates thereto
WO2024077160A3 (en) Compositions comprising prodrugs of hydroxyamate-based compounds and methods of making and using same
WO2024124023A3 (en) Carbonic anhydrase enzyme inhibitors and methods of use thereof
AU2021292433A8 (en) TLR7/8 antagonists and uses thereof
EP4285900A3 (en) Crystalline forms of deuterium-enriched pioglitazone
WO2024264072A3 (en) Parp inhibitors
WO2023168249A3 (en) Cysteamides, therapeutic compositions thereof, and related methods
WO2024220841A3 (en) Antiperovskite compositions and methods of use thereof
WO2023234891A3 (en) Novel acetylcholinesterase inhibitors
WO2024264070A3 (en) Akt inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23873679

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: AU2023350829

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 319844

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/A/2025/003568

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2025518779

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2025518779

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 202380070237.4

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2023350829

Country of ref document: AU

Date of ref document: 20230929

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025006089

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 202517038673

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20257013853

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2023873679

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 11202501951T

Country of ref document: SG

WWP Wipo information: published in national office

Ref document number: 11202501951T

Country of ref document: SG

ENP Entry into the national phase

Ref document number: 2023873679

Country of ref document: EP

Effective date: 20250429

WWP Wipo information: published in national office

Ref document number: 202517038673

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 1020257013853

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: MX/A/2025/003568

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 202380070237.4

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2023873679

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 112025006089

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20250327